Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Events & Presentations Presentation Corporate Presentation – May 2023 May 2, 2023 Upcoming Events Jefferies Healthcare Conference Jun 9, 2023 at 11:30 AM EDT Click here for webcast Add to Outlook Add to Google Calendar Past Events Q1 2023 Invivyd Earnings Conference Call May 11, 2023 at 4:30 PM EDT Click here for webcast H.C. Wainwright’s BioConnect Investor Conference May 2, 2023 at 4:00 PM EDT Click here for webcast Q4 2022 Invivyd Earnings Conference Call Mar 23, 2023 at 4:30 PM EDT Click here for webcast Cowen’s 43rd Annual Healthcare Conference Mar 6, 2023 at 2:10 PM EST Click here for webcast Supporting Materials Cowen’s 43rd Annual Healthcare Conference 2 MB J.P. Morgan 41st Annual Healthcare Conference Jan 9, 2023 Jefferies London Healthcare Conference Nov 15, 2022 at 4:25 PM GMT Click here for webcast Q3 2022 Invivyd Earnings Conference Call Nov 10, 2022 at 4:30 PM EST Click here for webcast H.C. Wainwright 24th Annual Global Investment Conference Sep 13, 2022 Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB Current page 1 Page 2 Next page next › Last page last »
Presentation Corporate Presentation – May 2023 May 2, 2023 Upcoming Events Jefferies Healthcare Conference Jun 9, 2023 at 11:30 AM EDT Click here for webcast Add to Outlook Add to Google Calendar Past Events Q1 2023 Invivyd Earnings Conference Call May 11, 2023 at 4:30 PM EDT Click here for webcast H.C. Wainwright’s BioConnect Investor Conference May 2, 2023 at 4:00 PM EDT Click here for webcast Q4 2022 Invivyd Earnings Conference Call Mar 23, 2023 at 4:30 PM EDT Click here for webcast Cowen’s 43rd Annual Healthcare Conference Mar 6, 2023 at 2:10 PM EST Click here for webcast Supporting Materials Cowen’s 43rd Annual Healthcare Conference 2 MB J.P. Morgan 41st Annual Healthcare Conference Jan 9, 2023 Jefferies London Healthcare Conference Nov 15, 2022 at 4:25 PM GMT Click here for webcast Q3 2022 Invivyd Earnings Conference Call Nov 10, 2022 at 4:30 PM EST Click here for webcast H.C. Wainwright 24th Annual Global Investment Conference Sep 13, 2022 Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB Current page 1 Page 2 Next page next › Last page last »
Jefferies Healthcare Conference Jun 9, 2023 at 11:30 AM EDT Click here for webcast Add to Outlook Add to Google Calendar
Cowen’s 43rd Annual Healthcare Conference Mar 6, 2023 at 2:10 PM EST Click here for webcast Supporting Materials Cowen’s 43rd Annual Healthcare Conference 2 MB
Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast
ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB
Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB
